Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1.
1H magnetic resonance spectroscopy
Neurochemical profile
SCA1
SCA14
Spinocerebellar ataxia
Journal
Cerebellum (London, England)
ISSN: 1473-4230
Titre abrégé: Cerebellum
Pays: United States
ID NLM: 101089443
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
accepted:
04
10
2020
pubmed:
17
10
2020
medline:
6
11
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
Autosomal-dominant spinocerebellar ataxias (SCA) are neurodegenerative diseases characterized by progressive ataxia. Here, we report on neurometabolic alterations in spinocerebellar ataxia type 1 (SCA1; SCA-ATXN1) and 14 (SCA14; SCA-PRKCG) assessed by non-invasive
Identifiants
pubmed: 33063293
doi: 10.1007/s12311-020-01201-y
pii: 10.1007/s12311-020-01201-y
pmc: PMC8004522
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-178Références
Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42:174–83.
doi: 10.1159/000358801
Hernandez-Castillo CR, King M, Diedrichsen J, Fernandez-Ruiz J. Unique degeneration signatures in the cerebellar cortex for spinocerebellar ataxias 2, 3, and 7. Neuroimage Clin. 2018;20:931–8.
doi: 10.1016/j.nicl.2018.09.026
Reetz K, Costa AS, Mirzazade S, Lehmann A, Juzek A, Rakowicz M, et al. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain. 2013;136:905–17.
doi: 10.1093/brain/aws369
Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885–94.
doi: 10.1016/S1474-4422(10)70183-6
Sun YM, Lu C, Wu ZY. Spinocerebellar ataxia: relationship between phenotype and genotype - a review. Clin Genet. 2016;90:305–14.
doi: 10.1111/cge.12808
Matilla-Duenas A, Goold R, Giunti P. Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum. 2008;7:106–14.
doi: 10.1007/s12311-008-0009-0
Yue S, Serra HG, Zoghbi HY, Orr HT. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum Mol Genet. 2001;10:25–30.
doi: 10.1093/hmg/10.1.25
Stricker S, Oberwahrenbrock T, Zimmermann H, Schroeter J, Endres M, Brandt AU, et al. Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1. PLoS One. 2011;6:e23024.
doi: 10.1371/journal.pone.0023024
Doss S, Rinnenthal JL, Schmitz-Hubsch T, Brandt AU, Papazoglou S, Lux S, et al. Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency. J Neurol. 2015;262:1927–35.
doi: 10.1007/s00415-015-7788-2
Doss S, Brandt AU, Oberwahrenbrock T, Endres M, Paul F, Rinnenthal JL. Metabolic evidence for cerebral neurodegeneration in spinocerebellar ataxia type 1. Cerebellum. 2014;13:199–206.
doi: 10.1007/s12311-013-0527-2
Krahe J, Binkofski F, Schulz JB, Reetz K, Romanzetti S. Neurochemical profiles in hereditary ataxias: a meta-analysis of magnetic resonance spectroscopy studies. Neurosci Biobehav Rev. 2020;108:854–65.
doi: 10.1016/j.neubiorev.2019.12.019
Joers JM, Deelchand DK, Lyu T, Emir UE, Hutter D, Gomez CM, et al. Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. Ann Neurol. 2018;83:816–29.
doi: 10.1002/ana.25212
Deelchand DK, Adanyeguh IM, Emir UE, Nguyen TM, Valabregue R, Henry PG, et al. Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single-voxel MRS at 3T. Magn Reson Med. 2015;73:1718–25.
doi: 10.1002/mrm.25295
Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717–20.
doi: 10.1212/01.wnl.0000219042.60538.92
Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry. 2004;19:136–43.
doi: 10.1002/gps.1042
Genis D, Matilla T, Volpini V, Rosell J, Davalos A, Ferrer I, et al. Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred: (CAG)n expansion and early premonitory signs and symptoms. Neurology. 1995;45:24–30.
doi: 10.1212/WNL.45.1.24
Robitaille Y, Schut L, Kish SJ. Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype. Acta Neuropathol. 1995;90:572–81.
doi: 10.1007/BF00318569
Ratai EM, Gilberto GR. Clinical magnetic resonance spectroscopy of the central nervous system. Handb Clin Neurol. 2016;135:93–116.
doi: 10.1016/B978-0-444-53485-9.00005-2
Emir UE, Brent Clark H, Vollmers ML, Eberly LE, Oz G. Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J Neurochem. 2013;127:660–8.
doi: 10.1111/jnc.12435
Mascalchi M, Tosetti M, Plasmati R, Bianchi MC, Tessa C, Salvi F, et al. Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1. Ann Neurol. 1998;43:244–52.
doi: 10.1002/ana.410430215
Oz G, Nelson CD, Koski DM, Henry PG, Marjanska M, Deelchand DK, et al. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci. 2010;30:3831–8.
doi: 10.1523/JNEUROSCI.5612-09.2010
Oz G, Hutter D, Tkac I, Clark HB, Gross MD, Jiang H, et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord. 2010;25:1253–61.
doi: 10.1002/mds.23067
Wullner U, Reimold M, Abele M, Burk K, Minnerop M, Dohmen BM, et al. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol. 2005;62:1280–5.
doi: 10.1001/archneur.62.8.1280
Wang PS, Liu RS, Yang BH, Soong BW. Regional patterns of cerebral glucose metabolism in spinocerebellar ataxia type 2, 3 and 6 : a voxel-based FDG-positron emission tomography analysis. J Neurol. 2007;254:838–45.
doi: 10.1007/s00415-006-0383-9
Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med. 2006;47:215–22.
pubmed: 16455626
Tondo G, Iaccarino L, Caminiti SP, Presotto L, Santangelo R, Iannaccone S, et al. The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease. Alzheimers Res Ther. 2020;12:50.
doi: 10.1186/s13195-020-00619-0
Endo H, Sekiguchi K, Ueda T, Kowa H, Kanda F, Toda T. Regional glucose hypometabolic spread within the primary motor cortex is associated with amyotrophic lateral sclerosis disease progression: a fluoro-deoxyglucose positron emission tomography study. eNeurologicalSci. 2017;6:74–9.
doi: 10.1016/j.ensci.2017.01.001
Firbank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, et al. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson’s disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry. 2017;88:310–6.
doi: 10.1136/jnnp-2016-313918
Lund TM, Risa O, Sonnewald U, Schousboe A, Waagepetersen HS. Availability of neurotransmitter glutamate is diminished when beta-hydroxybutyrate replaces glucose in cultured neurons. J Neurochem. 2009;110:80–91.
doi: 10.1111/j.1471-4159.2009.06115.x
Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res. 2014;39:1–36.
doi: 10.1007/s11064-013-1199-5
Cvetanovic M. Decreased expression of glutamate transporter GLAST in Bergmann glia is associated with the loss of Purkinje neurons in the spinocerebellar ataxia type 1. Cerebellum. 2015;14:8–11.
doi: 10.1007/s12311-014-0605-0
Adanyeguh IM, Henry PG, Nguyen TM, Rinaldi D, Jauffret C, Valabregue R, et al. In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7. Mov Disord. 2015;30:662–70.
doi: 10.1002/mds.26181
Valenzuela MJ, Jones M, Wen W, Rae C, Graham S, Shnier R, et al. Memory training alters hippocampal neurochemistry in healthy elderly. Neuroreport. 2003;14:1333–7.
pubmed: 12876468
Sanchez I, Balague E, Matilla-Duenas A. Ataxin-1 regulates the cerebellar bioenergetics proteome through the GSK3beta-mTOR pathway which is altered in Spinocerebellar ataxia type 1 (SCA1). Hum Mol Genet. 2016;25:4021–40.
doi: 10.1093/hmg/ddw242
Stucki DM, Ruegsegger C, Steiner S, Radecke J, Murphy MP, Zuber B, et al. Mitochondrial impairments contribute to Spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondria-targeted antioxidant MitoQ. Free Radic Biol Med. 2016;97:427–40.
doi: 10.1016/j.freeradbiomed.2016.07.005